Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 13/20 | 0.70 |
| ▸ | MAPK9 | P45984 | 11/20 | 0.70 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.67 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1557835 | 0.85 | MAPK3 (0.54) | MAPK10MAPK9PTK2MAPK3MAPK1 | |
| SCHEMBL12901796 | 0.85 | MAPK10 (0.68) | MAPK10MAPK9PTK2MAPK3MAPK1 | |
| SCHEMBL1232329 | 0.84 | MAPK10 (0.85) | MAPK10MAPK9PTK2JAK2JAK1 | |
| SCHEMBL1559534 | 0.83 | MAPK3 (0.53) | MAPK10MAPK9PTK2MAPK3MAPK1 | |
| SCHEMBL1232412 | 0.82 | MAPK10 (0.67) | MAPK10MAPK9PTK2MAPK1JAK2 | |
| SCHEMBL1231859 | 0.82 | MAPK10 (1.00) | MAPK10MAPK9PTK2 | |
| SCHEMBL1557791 | 0.82 | MAPK9 (0.65) | MAPK10MAPK9PTK2MAPK3MAPK1 | |
| SCHEMBL2185796 | 0.82 | MAPK10 (0.53) | MAPK10MAPK9PTK2MAPK3MAPK1 | |
| SCHEMBL1563037 | 0.82 | MAPK3 (0.51) | MAPK10MAPK9PTK2MAPK3MAPK1 | |
| SCHEMBL47302 | 0.81 | MAPK10 (0.84) | MAPK10MAPK9PTK2MAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102124000-A | Pyridine compounds | ASTRAZENECA AB | 2011-07-13 | — | — | CN | claimed |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | claimed |
| CN-102124000-B | Pyridine compounds | ASTRAZENECA AB | 2014-09-17 | — | — | CN | disclosed |
| EP-2303861-B1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2014-04-23 | — | — | EP | disclosed |
| EP-2303861-B1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2014-04-23 | — | — | EP | disclosed |
| US-8569298-B2 | Pyridine compounds | ASTRAZENECA AB (SE) | 2013-10-29 | — | — | US | disclosed |
| US-8569298-B2 | Pyridine compounds | ASTRAZENECA AB (SE) | 2013-10-29 | — | — | US | disclosed |
| US-8569298-B2 | Pyridine compounds | ASTRAZENECA AB (SE) | 2013-10-29 | — | — | US | disclosed |
| CN-102124000-A | Pyridine compounds | ASTRAZENECA AB | 2011-07-13 | — | — | CN | disclosed |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | disclosed |
| WO-2009153589-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166139-A1 | PYRIDINE COMPOUNDS | PTK2, PTK2B, PFKP | MAPK10 301/4885MAPK9 217/4885PTK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.